Free Trial

Sanofi (SNY) Stock Price, News & Analysis

Sanofi logo
$47.43 +1.25 (+2.71%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$47.44 +0.01 (+0.02%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sanofi Stock (NASDAQ:SNY)

Key Stats

Today's Range
$46.80
$47.54
50-Day Range
$45.64
$50.83
52-Week Range
$44.73
$60.12
Volume
3.64 million shs
Average Volume
2.36 million shs
Market Capitalization
$116.46 billion
P/E Ratio
11.40
Dividend Yield
3.37%
Price Target
$62.00
Consensus Rating
Buy

Company Overview

Sanofi Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

SNY MarketRank™: 

Sanofi scored higher than 87% of companies evaluated by MarketBeat, and ranked 125th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sanofi has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sanofi has only been the subject of 3 research reports in the past 90 days.

  • Read more about Sanofi's stock forecast and price target.
  • Earnings Growth

    Earnings for Sanofi are expected to grow by 8.94% in the coming year, from $4.36 to $4.75 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sanofi is 11.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sanofi is 11.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.

  • Price to Earnings Growth Ratio

    Sanofi has a PEG Ratio of 1.10. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Sanofi has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sanofi's valuation and earnings.
  • Percentage of Shares Shorted

    0.15% of the float of Sanofi has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sanofi has recently decreased by 16.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sanofi pays a meaningful dividend of 3.46%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Sanofi does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Sanofi is 38.46%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Sanofi will have a dividend payout ratio of 33.68% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

  • Read more about Sanofi's dividend.
  • Percentage of Shares Shorted

    0.15% of the float of Sanofi has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sanofi has recently decreased by 16.40%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sanofi has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 45 news articles for Sanofi this week, compared to 19 articles on an average week.
  • Search Interest

    21 people have searched for SNY on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    16 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sanofi insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Sanofi is held by insiders.

  • Percentage Held by Institutions

    Only 14.04% of the stock of Sanofi is held by institutions.

  • Read more about Sanofi's insider trading history.
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

SNY Stock Analysis - Frequently Asked Questions

Sanofi's stock was trading at $48.23 at the beginning of 2025. Since then, SNY stock has decreased by 1.7% and is now trading at $47.43.

Sanofi (NASDAQ:SNY) announced its quarterly earnings data on Thursday, July, 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by $0.06. The company's revenue for the quarter was down 7.0% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Sanofi: Kiadis Pharma, Principia BioPharma, Synthorx, Ablynx, Bioverativ, Aventis S.A., Ablynx N.V., and more.

Sanofi's top institutional shareholders include Boston Partners (0.16%), Envestnet Asset Management Inc. (0.14%), Equity Investment Corp (0.10%) and DAVENPORT & Co LLC (0.09%).
View institutional ownership trends
.

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanofi investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Record date for 6/12 Dividend
5/09/2025
Ex-Dividend for 6/12 Dividend
5/09/2025
Dividend Payable
6/12/2025
Last Earnings
7/31/2025
Today
8/08/2025
Next Earnings (Estimated)
10/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNY
CIK
1121404
Employees
82,878
Year Founded
2004

Price Target and Rating

High Price Target
$65.00
Low Price Target
$56.00
Potential Upside/Downside
+30.7%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$4.16
Trailing P/E Ratio
11.40
Forward P/E Ratio
10.88
P/E Growth
1.1
Net Income
$6.02 billion
Net Margins
21.47%
Pretax Margin
17.11%
Return on Equity
16.86%
Return on Assets
9.63%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
1.27
Quick Ratio
0.94

Sales & Book Value

Annual Sales
$44.46 billion
Price / Sales
2.62
Cash Flow
$5.47 per share
Price / Cash Flow
8.67
Book Value
$32.49 per share
Price / Book
1.46

Miscellaneous

Outstanding Shares
2,455,510,000
Free Float
2,430,957,000
Market Cap
$116.46 billion
Optionable
Optionable
Beta
0.48

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:SNY) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners